Menu Search
Equities

BioLine RX Ltd

YP2A:FRA

BioLine RX Ltd

Actions
  • Price (EUR)0.505
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-65.65%
  • Beta--
Data delayed at least 15 minutes, as of Jun 24 2024 07:12 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

  • Revenue in USD (TTM)11.66m
  • Net income in USD-49.15m
  • Incorporated2003
  • Employees79.00
  • Location
    BioLine RX LtdModi'in Technology Park2 HaMa'ayan StreetMODIIN 7177871IsraelISR
  • Phone+972 86429100
  • Fax+972 86429101
  • Websitehttps://www.biolinerx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.